tiprankstipranks
Trending News
More News >
Vicarious Surgical Inc. (RBOT)
:RBOT
US Market

Vicarious Surgical (RBOT) AI Stock Analysis

Compare
230 Followers

Top Page

RB

Vicarious Surgical

(NYSE:RBOT)

39Underperform
Vicarious Surgical's stock score reflects significant financial challenges as a pre-revenue company with high cash burn, offset by a moderately stable balance sheet. Technical analysis indicates bearish sentiment, compounded by valuation challenges due to negative earnings. While the earnings call showed strategic advancements, supply chain delays and NYSE compliance issues pose risks. Successful clinical trials and improved cash management will be critical for future performance.
Positive Factors
Investor Sentiment
RBOT is planning to submit a technical dossier that will enable treatment of first clinical patients, significantly boosting investor sentiment.
Technical Development
RBOT successfully built its first patient cart and surgeon console for formal preclinical testing.
Negative Factors
Cash Flow Concerns
The company will need to either reduce cash burn or find some sources of non-dilutive financing.
Leadership Stability
The CFO departure is seen as another challenge for RBOT to handle on its path towards gaining clearance.

Vicarious Surgical (RBOT) vs. S&P 500 (SPY)

Vicarious Surgical Business Overview & Revenue Model

Company DescriptionVicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
How the Company Makes MoneyVicarious Surgical makes money primarily through the sale and leasing of its robotic surgical systems to hospitals and surgical centers. The company may also generate revenue through service contracts and maintenance agreements, ensuring the optimal functionality of its robotic platforms. Additionally, Vicarious Surgical could engage in strategic partnerships with healthcare providers and institutions to expand the adoption of its technology. These partnerships may involve collaborative research, co-development of surgical techniques, and training programs for surgeons. Furthermore, as the company's technology advances, it may explore revenue opportunities through software licensing, offering AI-driven analytics and insights as a service to enhance surgical performance and patient outcomes.

Vicarious Surgical Financial Statement Overview

Summary
Vicarious Surgical is in its early developmental phase, characterized by zero revenue and significant operating losses. The balance sheet remains stable with low leverage, but the cash flows highlight operational cash burn, necessitating ongoing financing. Strategic focus on product development and future revenue generation will be crucial for financial improvement.
Income Statement
10
Very Negative
Vicarious Surgical has reported zero revenue consistently, indicating a pre-revenue stage company. This lack of revenue growth severely impacts the ability to assess profitability metrics like gross and net profit margins, which remain negative due to high operating losses.
Balance Sheet
40
Negative
The balance sheet reflects a moderate leverage position with a debt-to-equity ratio of 0.30 in 2024, highlighting a manageable level of debt. However, declining equity due to persistent losses could pose future risks. The positive equity ratio of 68.95% suggests some stability in financial structure despite challenges.
Cash Flow
20
Very Negative
The company demonstrates negative free cash flow, indicating cash outflows exceed operating inflows, which is typical for a development-stage firm. The negative operating cash flow to net income ratio shows operational challenges, though cash reserves have been bolstered through financing activities.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
0.00-1.85M-1.94M-316.00K0.00
EBIT
-66.56M-80.67M-80.08M-38.57M-12.98M
EBITDA
-66.56M-69.19M7.30M-34.80M-161.18K
Net Income Common Stockholders
-63.22M-71.07M89.16M-7.04M-12.88M
Balance SheetCash, Cash Equivalents and Short-Term Investments
49.10M98.18M116.21M173.51M16.87M
Total Assets
67.72M119.86M140.29M181.69M17.79M
Total Debt
13.79M14.83M15.69M1.34M110.00K
Net Debt
4.05M-37.99M-100.52M-172.17M-16.76M
Total Liabilities
21.02M21.89M29.25M98.95M935.00K
Stockholders Equity
46.70M97.97M111.05M82.74M16.85M
Cash FlowFree Cash Flow
-50.14M-63.98M-66.56M-34.59M-12.16M
Operating Cash Flow
-49.96M-62.30M-61.21M-33.30M-12.04M
Investing Cash Flow
6.86M-45.78M-5.35M-1.29M13.20M
Financing Cash Flow
8.00K44.70M9.14M192.16M13.52M

Vicarious Surgical Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.38
Price Trends
50DMA
7.30
Positive
100DMA
10.25
Negative
200DMA
9.27
Negative
Market Momentum
MACD
0.18
Positive
RSI
47.26
Neutral
STOCH
8.74
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RBOT, the sentiment is Negative. The current price of 7.38 is below the 20-day moving average (MA) of 7.71, above the 50-day MA of 7.30, and below the 200-day MA of 9.27, indicating a neutral trend. The MACD of 0.18 indicates Positive momentum. The RSI at 47.26 is Neutral, neither overbought nor oversold. The STOCH value of 8.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RBOT.

Vicarious Surgical Risk Analysis

Vicarious Surgical disclosed 73 risk factors in its most recent earnings report. Vicarious Surgical reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Vicarious Surgical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
$843.34M-15.96%22.60%41.26%
63
Neutral
$571.42M-11.33%31.28%-81.86%
52
Neutral
$5.15B3.02-44.64%2.83%16.44%-0.47%
51
Neutral
$3.21B-27.62%59.36%19.87%
43
Neutral
$576.64M-11.98%46.69%46.68%
42
Neutral
$194.49M271.41%85.03%53.73%
39
Underperform
$43.78M-104.36%-1455.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RBOT
Vicarious Surgical
7.38
-4.06
-35.49%
KIDS
OrthoPediatrics
23.07
-9.46
-29.08%
SIBN
SI-Bone
19.79
5.39
37.43%
TLSI
TriSalus Life Sciences
5.14
-5.01
-49.36%
RXST
RxSight
14.19
-48.45
-77.35%
PRCT
PROCEPT BioRobotics
58.07
-10.63
-15.47%

Vicarious Surgical Earnings Call Summary

Earnings Call Date:May 12, 2025
(Q1-2025)
|
% Change Since: -16.80%|
Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant strategic partnerships and progress toward clinical milestones while acknowledging ongoing challenges with cash burn and regulatory processes. Despite some concerns, there is optimism about achieving major milestones in 2025.
Q1-2025 Updates
Positive Updates
Strategic Hospital System Partnership
Vicarious Surgical announced a strategic partnership with UMass Memorial Medical Center to optimize robotic system implementation and enhance surgeon education.
Decrease in Operating Expenses
Total operating expenses decreased by 2% to $15.7 million in Q1 2025 compared to $16.1 million in Q1 2024.
Successful Development and Testing Progress
Completion of the first patient card and surgeon console for formal preclinical testing, and advancements in system integration and instrument production.
Optimism for 2025 Clinical Milestone
Anticipation of Vicarious Surgical evolving into a clinical-stage company in 2025 with the first clinical patients using the single-port surgical system.
Negative Updates
Continued Cash Burn and Financing Concerns
First quarter cash burn rate was $12 million, with expectations of $50 million for the full year 2025. Financing strategies are being evaluated due to limited cash reserves.
Supply Chain Challenges
Previous challenges with the supply chain were noted, though no recent changes or adjustments have affected the schedule.
Ongoing Regulatory and Approval Processes
The company is still undergoing regulatory approvals and dossier submissions, with expectations to begin first patient testing later in 2025.
Company Guidance
During Vicarious Surgical's 2025 First Quarter Earnings Call, the company provided guidance on several key metrics and strategic initiatives. The call highlighted the company's transition towards becoming a clinical-stage entity, anticipating the treatment of initial patients later in 2025 with its single-port surgical system. The company outlined its strategic focus on inventory buildup and rigorous testing, including sterility and biocompatibility, to ensure readiness for clinical trials. Financially, Vicarious Surgical reported total operating expenses of $15.7 million for Q1 2025, a slight decrease from the previous year, with R&D expenses accounting for $9.4 million. The firm's GAAP net loss was $15.4 million, or $2.60 per share, compared to a net loss of $17 million, or $2.90 per share, in Q1 2024. The call also discussed the company's cash position of approximately $37 million and a projected full-year cash burn of $50 million, emphasizing disciplined capital allocation and strategic financing plans. The company celebrated a new strategic partnership with UMass Memorial Medical Center, aimed at refining surgical workflows and enhancing surgeon education, underscoring its commitment to successful commercialization of its V1.0 system.

Vicarious Surgical Corporate Events

Delistings and Listing ChangesRegulatory Filings and Compliance
Vicarious Surgical Faces NYSE Non-Compliance Notice
Negative
Apr 11, 2025

On April 10, 2025, Vicarious Surgical received a notice from the NYSE indicating non-compliance with listing standards due to its market capitalization and stockholders’ equity both being below $50 million. The company has 45 days to submit a compliance plan to the NYSE, which, if accepted, will allow its stock to continue trading with a ‘.BC’ designation indicating below-criteria status. This notice does not affect the company’s operations or SEC reporting obligations, and Vicarious Surgical is exploring options to regain compliance.

Spark’s Take on RBOT Stock

According to Spark, TipRanks’ AI Analyst, RBOT is a Underperform.

The overall score for Vicarious Surgical’s stock is 38, reflecting significant financial challenges due to its early-stage status with zero revenue and high cash burn. Technical indicators point to bearish momentum, while valuation remains unattractive with a negative P/E. The earnings call highlighted both strategic advancements and operational delays, balancing the outlook slightly. The company’s future relies on successful clinical trials and managing supply chain issues.

To see Spark’s full report on RBOT stock, click here.

Executive/Board Changes
Vicarious Surgical Appoints New Chief Financial Officer
Positive
Mar 13, 2025

On March 13, 2025, Vicarious Surgical announced the appointment of Sarah Romano as Chief Financial Officer, effective April 1, 2025. Romano, with over two decades of financial experience, is expected to leverage her expertise in financial strategy and corporate development to drive the company’s financial objectives and success, particularly as Vicarious Surgical approaches its first clinical use cases later this year.

Executive/Board Changes
Vicarious Surgical Announces COO Retirement in 2025
Neutral
Feb 18, 2025

On February 12, 2025, Vicarious Surgical announced the planned retirement of its Chief Operating Officer, John Mazzola, effective April 1, 2025. Mazzola, who has nearly 40 years of experience in healthcare manufacturing and quality control, has been pivotal in advancing the company’s manufacturing processes and supply chain resilience, positioning Vicarious Surgical for upcoming clinical use cases and trials. His responsibilities will transition to Randy Clark, the company’s President.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.